These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18418222)

  • 1. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.
    Dawson SJ; Conus NM; Toner GC; Raleigh JM; Hicks RJ; McArthur G; Rischin D
    Anticancer Drugs; 2008 Jun; 19(5):547-52. PubMed ID: 18418222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
    Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients.
    Atallah V; Hocquelet A; Do Cao C; Zerdoud S; De La Fouchardiere C; Bardet S; Italiano A; Dierick-Galet A; Leduc N; Bonichon F; Leboulleux S; Godbert Y
    Thyroid; 2016 Aug; 26(8):1085-92. PubMed ID: 27370404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib therapy in metastatic papillary thyroid cancer.
    Gori S; Foglietta J; Rossi M; Hamzaj A; Stocchi L; Galuppo C; Picece V; Puxeddu E; Furlani L
    Tumori; 2013; 99(6):285e-7e. PubMed ID: 24503805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis.
    Pasqualetti G; Ricci S; Boni G; Tognini S; Polini A; Mariani G; Ferdeghini M; Monzani F
    Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):171-6. PubMed ID: 22533521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.
    Jeong WJ; Mo JH; Park MW; Choi IJ; An SY; Jeon EH; Ahn SH
    Cancer Biol Ther; 2011 Sep; 12(5):458-65. PubMed ID: 21725210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
    Bikas A; Kundra P; Desale S; Mete M; O'Keefe K; Clark BG; Wray L; Gandhi R; Barett C; Jelinek JS; Wexler JA; Wartofsky L; Burman KD
    Eur J Endocrinol; 2016 Mar; 174(3):373-80. PubMed ID: 26671977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature.
    Kaldrymides P; Kostoglou-Athanassiou I; Gkountouvas A; Veniou E; Ziras N
    Endocrine; 2010 Feb; 37(1):6-10. PubMed ID: 20963554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting RET for thyroid cancer therapy.
    Lanzi C; Cassinelli G; Nicolini V; Zunino F
    Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.
    Bugalho MJ; Domingues R; Borges A
    Oncologist; 2009 Nov; 14(11):1083-7. PubMed ID: 19887470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
    Fagin JA; Tuttle RM; Pfister DG
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2621-4. PubMed ID: 20525911
    [No Abstract]   [Full Text] [Related]  

  • 13. The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature.
    Pasqualetti G; Ricci S; Dardano A; Ferdeghini M; Del Tacca M; Monzani F
    Mini Rev Med Chem; 2011 Aug; 11(9):746-52. PubMed ID: 21707530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
    Ravaud A; de la Fouchardière C; Caron P; Doussau A; Do Cao C; Asselineau J; Rodien P; Pouessel D; Nicolli-Sire P; Klein M; Bournaud-Salinas C; Wemeau JL; Gimbert A; Picat MQ; Pedenon D; Digue L; Daste A; Catargi B; Delord JP
    Eur J Cancer; 2017 May; 76():110-117. PubMed ID: 28301826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
    Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM
    Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib for the treatment of thyroid cancer.
    Gómez-Sáez JM
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1345-1352. PubMed ID: 27677828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
    Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
    J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors.
    Cirello V; Vaira V; Grassi ES; Vezzoli V; Ricca D; Colombo C; Bosari S; Vicentini L; Persani L; Ferrero S; Fugazzola L
    Oncotarget; 2017 Feb; 8(6):9752-9766. PubMed ID: 28039458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motesanib diphosphate in progressive differentiated thyroid cancer.
    Sherman SI; Wirth LJ; Droz JP; Hofmann M; Bastholt L; Martins RG; Licitra L; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Schlumberger MJ;
    N Engl J Med; 2008 Jul; 359(1):31-42. PubMed ID: 18596272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.